These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 974574)

  • 61. [Melanocytes and the hormonology of pigment reactions].
    Voĭtkevich AA
    Usp Sovrem Biol; 1966; 61(3):471-90. PubMed ID: 4301962
    [No Abstract]   [Full Text] [Related]  

  • 62. [Research of the melanocytodilator principle during some hyperchromies].
    DESAUX A; YVRARD H; ASSELIN
    Ann Dermatol Syphiligr (Paris); 1945; 5():328-30. PubMed ID: 21064353
    [No Abstract]   [Full Text] [Related]  

  • 63. Sparing phenomenon in salt and pepper pigmentation of systemic sclerosis: an unusual observation.
    Ghosh SK; Mondal S
    Clin Exp Dermatol; 2022 May; 47(5):967-969. PubMed ID: 34939220
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunoreactive beta-melanocyte-stimulating hormone in cerebrospinal fluid.
    Smith AG; Shuster S
    Lancet; 1976 Jun; 1(7973):1321-2. PubMed ID: 58311
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Parapsoriasis in gout, with cervical and brachial leuko-melanoderma].
    BLUM P; LARDAT M; PAYENNEVILLE H
    Ann Dermatol Syphiligr (Paris); 1946 Sep; 6(9):491. PubMed ID: 20292602
    [No Abstract]   [Full Text] [Related]  

  • 66. Supraventine sparing of salt-and-pepper pigmentation in a patient with systemic sclerosis.
    Sindhuja T; Danish M; Gupta V
    Indian J Dermatol Venereol Leprol; 2022; 88(6):812-813. PubMed ID: 35962515
    [No Abstract]   [Full Text] [Related]  

  • 67. Development and significance of heterochromia of the iris.
    Gladstone RM
    Arch Neurol; 1969 Aug; 21(2):184-91. PubMed ID: 5797351
    [No Abstract]   [Full Text] [Related]  

  • 68. Hormone patterns after electroconvulsive therapy.
    Vargas L
    Lancet; 1983 Feb; 1(8320):365. PubMed ID: 6130371
    [No Abstract]   [Full Text] [Related]  

  • 69. Disappearance of immunoreactive alpha-melanotrophin from rat plasma following occlusion of different regions of the vascular bed.
    Lambert TR; Wilson JF
    J Endocrinol; 1981 Mar; 88(3):437-41. PubMed ID: 7217830
    [TBL] [Abstract][Full Text] [Related]  

  • 70. THERAPY OF MELANIN HYPERPIGMENTATION.
    BECKER SW
    Postgrad Med; 1965 Feb; 37():198-201. PubMed ID: 14255414
    [No Abstract]   [Full Text] [Related]  

  • 71. Ultraviolet autorepigmentation in scleroderma.
    Freiman A; Khanna M; Muhn CY; Billick RC
    J Am Acad Dermatol; 2003 Nov; 49(5):960-1. PubMed ID: 14576693
    [No Abstract]   [Full Text] [Related]  

  • 72. Decreased sebum excretion in chronic renal failure.
    Shuster S; Goolamali SK; Smith AG; Thody AJ; Alvarez-Ude F; Kerr DN
    Br Med J; 1976 Jan; 1(6000):23-4. PubMed ID: 1247719
    [No Abstract]   [Full Text] [Related]  

  • 73. Systemic sclerosis 'state of the art' 1995.
    Black CM
    Scand J Rheumatol; 1995; 24(4):194-6. PubMed ID: 7481580
    [No Abstract]   [Full Text] [Related]  

  • 74. Reticular acropigmentation of Kitamura: a study of HLA antigen typing.
    Bocanegra OC; Navarta LM; Gandur A
    Br J Dermatol; 1995 Nov; 133(5):819-20. PubMed ID: 8555048
    [No Abstract]   [Full Text] [Related]  

  • 75. Turgenev's 'living relic': an early description of scleroderma?
    Ellis RM; Moitra R; North N
    J R Soc Med; 2005 Aug; 98(8):372-4. PubMed ID: 16055908
    [No Abstract]   [Full Text] [Related]  

  • 76. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.
    Viswanath V; Phiske MM; Gopalani VV
    Indian J Dermatol; 2013 Jul; 58(4):255-68. PubMed ID: 23918994
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunoreactive beta-melanocyte-stimulating hormone and melanin pigmentation in systemic sclerosis.
    Smith AG; Holti GS; Shuster S
    Br Med J; 1976 Sep; 2(6038):733-4. PubMed ID: 974574
    [No Abstract]   [Full Text] [Related]  

  • 78. [Melanin thesaurismosis with special reference to melanocyte stimulating hormone (MSH) secretion anomalies].
    Abe K
    Nihon Rinsho; 1972 Nov; 30(11):2243-8. PubMed ID: 4346765
    [No Abstract]   [Full Text] [Related]  

  • 79. Plasma immunoreactive beta-melanocyte-stimulating hormone in chronic liver disease and fulminant hepatic failure.
    Smith AG; Shuster S; Bomford A; Williams R
    J Invest Dermatol; 1978 Jun; 70(6):326-7. PubMed ID: 649979
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chloasma, oral contraceptives, and plasma immunoreactive beta-melanocyte-stimulating hormone.
    Smith AG; Shuster S; Thody AJ; Peberdy M
    J Invest Dermatol; 1977 Apr; 68(4):169-70. PubMed ID: 845449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.